CO VID-19 vaccines efficacy and infection features in patients with systemic sclerosis:A single-center cohort study
10.19723/j.issn.1671-167X.2024.06.015
- VernacularTitle:系统性硬化症患者新型冠状病毒感染特点及疫苗接种效果:一项单中心队列研究
- Author:
Wei PAN
1
;
Yun LI
;
Junjia LUO
;
Chun LI
;
Hua YE
;
Xue LI
;
Yuan JIA
Author Information
1. 北京大学人民医院风湿免疫科,北京 100044;中国人民解放军联勤保障部队第九二三医院检验科,南宁 530004
- Publication Type:Journal Article
- Keywords:
Systemic sclerosis;
COVID-19;
COVID-19 vaccines
- From:
Journal of Peking University(Health Sciences)
2024;56(6):1041-1046
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To comprehensively understand the COVID-19 vaccination and infection status among patients with systemic sclerosis(SSc).Methods:We conducted a retrospective analysis of pa-tients diagnosed with SSc who were hospitalized in the Rheumatology and Immunology Department of Pe-king University People's Hospital from January 2016 to March 2023.We collected detailed clinical cha-racteristics,vaccination status,and infection details through a systematic review of medical records and telephone follow-ups with the SSc patients.Results:Out of 236 identified patients,99 SSc patients par-ticipated in the follow-up.This cohort included 41 patients with limited SSc,28 with diffuse SSc,and 30 with SSc overlap syndromes.Treatments varied,with glucocorticoids administered to 57.58％of pa-tients,immunosuppressants to 56.57％,biologic agents to 7.07％,and small molecule targeted thera-pies to 6.06％.Notably,49 patients had received the COVID-19 vaccine.Between November 2022 and March 2023,a total of 81 patients contracted COVID-19.The infection rate among those who received three doses or more(19/29,65.5％)was significantly lower compared with unvaccinated patients(45/50,90.0％,P=0.007).Fourteen of these patients required hospitalization due to COVID-19.Further-more,26 patients reported exacerbation of SSc symptoms post-infection,which included severe manifesta-tions,such as Raynaud phenomenon,skin lesions,fingertip ulcers,pulmonary hypertension,and inter-stitial lung disease.Compared with healthy cohabitants,the SSc patients exhibited more severe symptoms following COVID-19,including fever(36.71％)and fatigue(35.44％).Multivariate regression analy-sis identified subcutaneous calcinosis(OR=7.713,95％CI:1.142-45.051)and positivity for anti-centromere antibodies(OR=9.210,95％CI:1.211-70.028)as independent risk factors for hospitali-zation due to COVID-19.Conclusion:Vaccination is both effective and safe in preventing COVID-19 among SSc patients.Additionally,it underscores that these patients experience exacerbation of their un-derlying disease and more severe COVID-19 symptoms compared with individuals without underlying con-ditions.Thus,proactive prevention,continuous monitoring,and early treatment of COVID-19 are of sig-nificant importance for the health and well-being of SSc patients.Timely interventions can help mitigate the impact of infections and improve overall patient outcomes.
